Tarsus Pharmaceuticals, Inc. to Present at the Jefferies Virtual Healthcare ConferenceGlobeNewsWire • 05/24/21
Tarsus Pharmaceuticals, Inc. Reports First Quarter 2021 Financial Results and Provides Business and Clinical UpdatesGlobeNewsWire • 05/11/21
Tarsus Pharmaceuticals, Inc. Announces FDA Acceptance of Investigational New Drug Application for TP-05 for Lyme Disease PreventionGlobeNewsWire • 05/04/21
Tarsus Pharmaceuticals, Inc. Presents Results of Pioneering Atlas Study at ARVO 2021 Annual Meeting Demonstrating the Functional and Psychosocial Impact of Demodex BlepharitisGlobeNewsWire • 05/03/21
Tarsus Pharmaceuticals, Inc. to Present at the BofA Securities 2021 Virtual Health Care ConferenceGlobeNewsWire • 04/27/21
Tarsus Pharmaceuticals, Inc. Reports Full-Year 2020 Financial Results and Business and Clinical UpdatesGlobeNewsWire • 03/31/21
Tarsus Pharmaceuticals and LianBio Announce Strategic Partnership to Develop and Commercialize TP-03 in Greater China for the Treatment of Demodex Blepharitis and Meibomian Gland DiseaseGlobeNewsWire • 03/29/21
Tarsus Pharmaceuticals, Inc. Appoints Dianne Whitfield as Chief Human Resources OfficerGlobeNewsWire • 01/07/21
Tarsus Pharmaceuticals, Inc. Announces Type C Meeting with FDA Regarding NDA Submission Requirements for Lead Candidate TP-03GlobeNewsWire • 12/23/20
Tarsus Pharmaceuticals, Inc. Announces Inclusion in the Russell 3000® Index and Russell 2000® IndexGlobeNewsWire • 12/21/20
Tarsus Pharmaceuticals, Inc. to Present at the Jefferies Virtual London Healthcare ConferenceGlobeNewsWire • 11/14/20
Tarsus Pharmaceuticals, Inc. Announces Closing of Initial Public Offering and Full Exercise by the Underwriters of Option to Purchase Additional SharesGlobeNewsWire • 10/20/20